Cargando…
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We investigated the efficacy and sa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575486/ https://www.ncbi.nlm.nih.gov/pubmed/32363427 http://dx.doi.org/10.1007/s10637-020-00925-2 |
_version_ | 1783597819735572480 |
---|---|
author | Li, Ling Kong, Fei Zhang, Lei Li, Xin Fu, Xiaorui Wang, Xinhua Wu, Jingjing Zhang, Fangwen Ren, Liangliang Zhang, Mingzhi |
author_facet | Li, Ling Kong, Fei Zhang, Lei Li, Xin Fu, Xiaorui Wang, Xinhua Wu, Jingjing Zhang, Fangwen Ren, Liangliang Zhang, Mingzhi |
author_sort | Li, Ling |
collection | PubMed |
description | Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We investigated the efficacy and safety of apatinib for relapsed and refractory nasopharyngeal carcinoma in an open-label, single-arm, phase II clinical trial. Fifty-one patients with relapsed and refractory nasopharyngeal carcinoma in the First Affiliated Hospital, Zhengzhou University, who met the inclusion criteria were enrolled in the study. All patients received apatinib at an initial dose of 500 mg daily (1 cycle = 28 days). The primary and secondary endpoints were overall response rate, progression-free survival, and overall survival. We evaluated treatment effects and recorded apatinib-related adverse events by performing regular follow-ups and workup. The overall response rate (complete and partial responses) was 31.37% (16/51). The median overall survival and progression-free survival were 16 (95% CI, 9.32–22.68) and 9 months (95% CI, 5.24–12.76), respectively. Most patients tolerated treatment-related adverse events of grades 1 and 2; hypertension (29, 56.86%), proteinuria (25, 49.02%), and hand–foot syndrome (27, 52.94%) were the most common adverse events. There were no treatment-related deaths. Apatinib showed good efficacy and safety in patients with relapsed and refractory NPC. |
format | Online Article Text |
id | pubmed-7575486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-75754862020-10-21 Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study Li, Ling Kong, Fei Zhang, Lei Li, Xin Fu, Xiaorui Wang, Xinhua Wu, Jingjing Zhang, Fangwen Ren, Liangliang Zhang, Mingzhi Invest New Drugs Phase II Studies Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We investigated the efficacy and safety of apatinib for relapsed and refractory nasopharyngeal carcinoma in an open-label, single-arm, phase II clinical trial. Fifty-one patients with relapsed and refractory nasopharyngeal carcinoma in the First Affiliated Hospital, Zhengzhou University, who met the inclusion criteria were enrolled in the study. All patients received apatinib at an initial dose of 500 mg daily (1 cycle = 28 days). The primary and secondary endpoints were overall response rate, progression-free survival, and overall survival. We evaluated treatment effects and recorded apatinib-related adverse events by performing regular follow-ups and workup. The overall response rate (complete and partial responses) was 31.37% (16/51). The median overall survival and progression-free survival were 16 (95% CI, 9.32–22.68) and 9 months (95% CI, 5.24–12.76), respectively. Most patients tolerated treatment-related adverse events of grades 1 and 2; hypertension (29, 56.86%), proteinuria (25, 49.02%), and hand–foot syndrome (27, 52.94%) were the most common adverse events. There were no treatment-related deaths. Apatinib showed good efficacy and safety in patients with relapsed and refractory NPC. Springer US 2020-05-03 2020 /pmc/articles/PMC7575486/ /pubmed/32363427 http://dx.doi.org/10.1007/s10637-020-00925-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Phase II Studies Li, Ling Kong, Fei Zhang, Lei Li, Xin Fu, Xiaorui Wang, Xinhua Wu, Jingjing Zhang, Fangwen Ren, Liangliang Zhang, Mingzhi Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study |
title | Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study |
title_full | Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study |
title_fullStr | Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study |
title_full_unstemmed | Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study |
title_short | Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study |
title_sort | apatinib, a novel vegfr-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study |
topic | Phase II Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575486/ https://www.ncbi.nlm.nih.gov/pubmed/32363427 http://dx.doi.org/10.1007/s10637-020-00925-2 |
work_keys_str_mv | AT liling apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT kongfei apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT zhanglei apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT lixin apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT fuxiaorui apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT wangxinhua apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT wujingjing apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT zhangfangwen apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT renliangliang apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy AT zhangmingzhi apatinibanovelvegfr2tyrosinekinaseinhibitorforrelapsedandrefractorynasopharyngealcarcinomadatafromanopenlabelsinglearmexploratorystudy |